Clinical progression of lobaplatin in combination chemotherapy for patients with recurrence or metastatic cancer  

洛铂联合方案在化疗后进展的晚期癌症中临床研究进展(英文)

作　　者：Yu Peng Jiangkui Liu Qiang Lin 

机构地区：[1]Hebei North University [2]Department of Oncology, Hebei Medical University, Affiliated North China Petroleum Bureau General Hospital [3]Department of Gastroenterology, Hebei Medical University, Affiliated North China Petroleum Bureau General Hospital

出　　处：《The Chinese-German Journal of Clinical Oncology》2014年第8期386-391,共6页中德临床肿瘤学杂志（英文版）

基　　金：Supported by a grant from the Science and Technology Department oHebei Province(No.072761711)

摘　　要：The platinum-based combination chemotherapy has become one of the major modalities in anti-cancer treatment. After the first-line chemotherapy, many patients need further chemotherapy because of recurrence or metastasis. Lobaplatin is one of the third generation platinum drugs,and this article briefly reviews the clinical progression of Iobaplatin in combination chemotherapy for patients with recurrence or metastatic cancer.

关 键 词：Iobaplatin CHEMOTHERAPY RECURRENCE METASTASIS combination chemotherapy 

分 类 号：R730.5[医药卫生—肿瘤]